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HeBACKGROUND Little is known about the incidence of prosthesis-patient mismatch (PPM) and its impact on outcomes
after transcatheter aortic valve replacement (TAVR).
OBJECTIVES The objectives of this study were: 1) to compare the incidence of PPM in the TAVR and surgical aortic
valve replacement (SAVR) randomized control trial (RCT) arms of the PARTNER (Placement of AoRTic TraNscathetER
Valves) I Trial cohort A; and 2) to assess the impact of PPM on regression of left ventricular (LV) hypertrophy and
mortality in these 2 arms and in the TAVR nonrandomized continued access (NRCA) registry cohort.
METHODS The PARTNER Trial cohort A randomized patients 1:1 to TAVR or bioprosthetic SAVR. Postoperative PPM was
deﬁned as absent if the indexed effective oriﬁce area (EOA) was >0.85 cm2/m2, moderate if the indexed EOA was $0.65
but #0.85 cm2/m2, or severe if the indexed EOA was <0.65 cm2/m2. LV mass regression and mortality were analyzed
using the SAVR-RCT (n ¼ 270), TAVR-RCT (n ¼ 304), and TAVR-NRCA (n ¼ 1,637) cohorts.
RESULTS The incidence of PPM was 60.0% (severe: 28.1%) in the SAVR-RCT cohort versus 46.4% (severe: 19.7%)
in the TAVR-RCT cohort (p < 0.001) and 43.8% (severe: 13.6%) in the TAVR-NRCA cohort. In patients with an aortic
annulus diameter <20 mm, severe PPM developed in 33.7% undergoing SAVR compared with 19.0% undergoing TAVR
(p¼0.002). PPMwas an independent predictor of less LVmass regression at 1 year in the SAVR-RCT (p¼0.017) and TAVR-
NRCA (p¼ 0.012) cohorts but not in the TAVR-RCT cohort (p¼ 0.35). Severe PPM was an independent predictor of 2-year
mortality in the SAVR-RCT cohort (hazard ratio [HR]: 1.78; p¼0.041) but not in the TAVR-RCT cohort (HR: 0.58; p¼ 0.11).
In the TAVR-NRCA cohort, severe PPM was not a predictor of 1-year mortality in all patients (HR: 1.05; p ¼ 0.60) but did
independently predict mortality in the subset of patients with no post-procedural aortic regurgitation (HR: 1.88; p¼0.02).
CONCLUSIONS In patients with severe aortic stenosis and high surgical risk, PPM is more frequent andmore often severe
after SAVR than TAVR. Patients with PPM after SAVR have worse survival and less LV mass regression than those without
PPM. Severe PPMalso has a signiﬁcant impact on survival after TAVR in the subset of patientswith no post-procedural aortic
regurgitation. TAVRmaybepreferable toSAVR inpatientswith a small aortic annuluswhoare susceptible toPPMtoavoid its
adverse impact on LV mass regression and survival. (The PARTNER Trial: Placement of AoRTic TraNscathetER Valve Trial;
NCT00530894) (J Am Coll Cardiol 2014;64:1323–34) © 2014 by the American College of Cardiology Foundation.m the *Québec Heart and Lung Institute/Institut Universitaire de Cardiologie et de Pneumologie de Québec, Laval University,
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AR = aortic regurgitation
AS = aortic stenosis
BMI = body mass index
BSA = body surface area
CI = conﬁdence interval
EOA = effective oriﬁce area
HR = hazard ratio
LV = left ventricular
LVOT = left ventricular
outﬂow tract
NRCA = nonrandomized
continued access
PPM = prosthesis-patient
mismatch
RCT = randomized controlled
trial
SAVR = surgical aortic valve
replacement
STS = Society of Thoracic
Surgeons
TAVR = transcatheter aortic
valve replacement
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1324SEE PAGE 1335P rosthesis-patient mismatch (PPM) oc-curs when the effective oriﬁce area(EOA) of a normally functioning pros-
thetic valve is too small in relation to patient
body size. Several studies have reported
that PPM is frequent (20% to 70%) and has
a negative impact on short- and long-term
outcomes after surgical aortic valve replace-
ment (SAVR) for aortic stenosis (AS) (1). A
recent meta-analysis reported that moderate
and severe PPM are associated with a 1.2- and
1.8-fold increase in the risk of all-cause mor-
tality, respectively (2). Thus, it seems impor-
tant to implement preventive strategies to
avoid PPM without increasing operative risk.
Transcatheter aortic valve replacement
(TAVR) has emerged as a valid alternative to
SAVR in selected patients (3,4). Previous
nonrandomized studies suggested that TAVR
may be associated with a lower incidence
of PPM compared with SAVR (5,6). Some
studies reported that PPM is associated with
less regression of left ventricular (LV) hy-
pertrophy, less improvement in patientfunctional status, and increased mortality after TAVR
(7,8), whereas others found no signiﬁcant impact ofe, Stanford, California; zzDepartment of Thoracic and Cardiova
of the University of Pennsylvania, Philadelphia, Pennsylvania; kkU
, Canada; {{University of Virginia Medical Center, Charlottesville,
linical Research Institute, Durham, North Carolina. The PARTNE
urrent analysis was carried out by academic investigators and at
the PARTNER Publications Ofﬁce. Dr. Pibarot holds the Canada
f Health Research, Ottawa, Ontario, Canada; and has received res
r. Weissman has received grant support from Boston Scientiﬁc Co
rom the National Institutes of Health,Washington, DC. Dr. Kodali is
ltant for Edwards Lifesciences Corporation; a member of the stee
member of the scientiﬁc advisory board of Thubrikar Aortic Valve In
fesciences Corporation relating to his participation as an unpaid m
ni is a member of the PARTNER Trial Steering Committee; and a co
. JudeMedical Inc., andDirectFlow.Dr.Miller is supported by anR0
. HL67025; has received travel reimbursements from Edwards Life
the PARTNER Trial Executive Committee; and has received cons
., andMedtronic Inc. Dr. Svenssonhas received travel reimburseme
an unpaid member of the PARTNER Trial Executive Committee; h
tual Property Rights/Royalties from Posthorax. Dr. Herrmann has
orporation, Edwards Lifesciences Corporation, Medtronic Inc., S
nsulting fees/honoraria fromPaieon andW. L. Gore &Associates In
ifesciences Corporation related to work as an unpaid memb
abau has received grant support from Boston Scientiﬁc Corpora
nsulting fees/honoraria from AstraZeneca, Bristol-Myers Squibb,
ring-Plough, and Regeneron. Dr. Webb is a member of the PAR
fees from Edwards Lifesciences Corporation. Dr. Lim has receiv
, Guerbet, and St. Jude Medical Inc. Dr. Leon has received
related to work as an unpaidmember of the PARTNER Trial Execu
o relationships relevant to the contents of this paper to disclose.
is manuscript’s audio summary by JACC Editor-in-Chief Dr. Valen
o listen to this issue’s audio summary by JACC Editor-in-Chief Dr
received April 6, 2014; revised manuscript received June 3, 2014PPM on outcomes (9,10). No randomized trial has
published data comparing TAVR with SAVR with
respect to the incidence and clinical impact of PPM.The PARTNER (Placement of AoRTic TraNscathetER
Valves) trial was a multicenter, randomized con-
trolled trial (RCT) comparing TAVR with SAVR in
high-risk patients with severe AS (cohort A) (3,4,11).
Trial results showed that TAVR was noninferior
to SAVR with no difference in 2-year all-cause mor-
tality, cardiovascular mortality, or rehospitalization
for heart failure (3,4). The objectives of this study
were to 1) compare the incidence of PPM in the
TAVR- and SAVR-RCT arms of the PARTNER I Trial
cohort A; and 2) examine PPM’s impact on regression
of LV hypertrophy and on mortality in the RCT arms
and in the TAVR-nonrandomized continued access
(NRCA) registry of PARTNER IA.
METHODS
STUDY DESIGN AND PATIENT POPULATION. In a 1:1
ratio, cohort A of the PARTNER Trial randomized
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1325symptomatic AS between SAVR and TAVR with the
Edwards-SAPIEN heart valve system (Edwards Life-
sciences Corp., Irvine, California) (Online Figure 1)
(3). The trial’s design, inclusion and exclusion
criteria, and primary results have been reported
(3,11). These patients had severe AS with an aortic
valve area <0.8 cm2 (or indexed aortic valve area <0.5
cm2/m2) and either resting or inducible mean gradient
>40 mm Hg or peak jet velocity >4 m/s. They were
symptomatic from AS (New York Heart Association
functional class $2) and were at high surgical risk
as deﬁned by a predicted risk of death of $15% by
30 days after conventional surgery. Exclusion criteria
included bicuspid or noncalciﬁed valve, coronary
artery disease requiring revascularization, an LV
ejection fraction #20%, an aortic annulus diameter
<18 mm or >25 mm, severe mitral regurgitation or
aortic regurgitation (AR), and an aortic bioprosthesis.
For patients assigned to SAVR, the study protocol
strongly discouraged the use of surgical valves other
than Edwards bovine bioprostheses and excluded
patients in whom the need for a root enlargement
was recognized in advance. Nonetheless, for various
reasons, 10% of the surgical valves were not Edwards
valves, and intraoperative ﬁndings led to root en-
largement in 2 patients and root replacement in
2 patients.
Patients assigned to the TAVR group underwent
transfemoral or transapical placement of the aortic
valve on the basis of whether peripheral arteries
could accommodate the large sheaths required (22-F
for the 23-mm valve and 24-F for the 26-mm valve)
(Online Figure 1). Furthermore, 1,776 patients were
enrolled in the high-risk TAVR-NRCA cohort (Online
Figure 1), and the inclusion and exclusion criteria
for this registry were the same as those for the cohort
A RCT. In addition, given that paravalvular AR
has been shown to be a powerful predictor of mor-
tality in the TAVR arm of the PARTNER I Trial
cohort A (3) and that it may confound the association
between PPM and outcomes, we also assessed the
impact of PPM in the subset of the patients in the
TAVR-NRCA group (n ¼ 835) with no or trace post-
procedural AR.
Echocardiograms were obtained at baseline and
at 7 days, 30 days, 6 months, 1 year, and 2 years
post-procedure. For this post-hoc analysis, we
included patients in the SAVR-RCT and TAVR-RCT
groups and patients in the TAVR-NRCA group in
the as-treated population with a post-implant
echocardiogram available. This analysis included
270 patients in the SAVR-RCT group, 304 patients in
the TAVR-RCT group, and 1,637 patients in the
TAVR-NRCA group (Online Figure 1). The ﬁrst post-implant echocardiogram was the 7-day echocardio-
gram in 84.1% of the patients in the SAVR-RCT
group and 89.5% of the patients in the TAVR-RCT
group (p ¼ 0.06).
DOPPLER-ECHOCARDIOGRAPHIC MEASUREMENTS.
All baseline and follow-up echocardiograms were
interpreted by an independent core laboratory
housed at the Duke Clinical Research Institute. Study
work ﬂow, reproducibility testing, image acquisition
and analysis, and quality assurance data have been
published (12).
Ventricular size and function and valvular function
were measured according to previously published
guidelines (13,14). LV volumes and ejection fraction
were measured using the biplane Simpson formula.
LV mass was calculated using the formula recom-
mended by the American Society of Echocardiogra-
phy (13). The stroke volume was measured in the left
ventricular outﬂow tract (LVOT) with the use of the
diameter and velocity measured just underneath the
prosthesis stent for both surgical and transcatheter
valves. The EOA was calculated as the LVOT stroke
volume divided by the aortic jet velocity time integral
and was indexed for body surface area (BSA). An
integrative, semiquantitative approach was used to
assess the severity of central, paravalvular, and total
regurgitation (12,14). The results of the comparison of
the echocardiographic ﬁndings in the TAVR-RCT
versus SAVR-RCT arms of the PARTNER Trial cohort
A have been published (15).
DEFINITION OF PPM. The ﬁrst available post-implant
(7 days, 30 days, or 6 months) echocardiogram
showing EOA indexed for BSA was used to identify
and quantify PPM. The severity of PPM was graded
from the echocardiograms using the indexed EOA,
with absence deﬁned as >0.85 cm2/m2, moderate
deﬁned as $0.65 and #0.85 cm2/m2, and severe
deﬁned as <0.65 cm2/m2 (1,2).
STUDY ENDPOINTS. The study endpoints were
regression of LV mass at 1 year and all-cause mortality
at 2 years for the RCT cohort. For the TAVR-NRCA
cohort, 1-year mortality was used as the endpoint
because events were not adjudicated beyond this
time point in the registry cohort.
STATISTICAL ANALYSIS. Continuous variables are
presented as mean  SD or median (interquartile
range) for variables with a skewed distribution and
compared with the use of the Student t test or the
Wilcoxon rank-sum test. The normality of variables
was assessed with the Kolmogorov-Smirnov test.
Categoric variables were compared with the use of the
chi-square or the Fisher exact tests. The Fisher exact
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1326test was used when the expected cell frequency
was <5.
Absolute and percent changes in LV mass were
calculated using paired data at baseline and 1 year
and were compared between PPM groups in each
treatment group (TAVR-RCT, SAVR-RCT, TAVR-
NRCA). Multivariable analysis was performed with
linear regression. Survival curves for time-to-event
variables were constructed on the basis of all avail-
able follow-up data with the use of Kaplan-MeierNo PPM Moderat
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controlled trial; SAVR ¼ surgical aortic valve replacement; TAVR ¼ tranestimates and compared with the use of the log-rank
test. Multivariable analysis was performed in each
treatment group with the Cox proportional hazards
model. PPM was entered into the models in binary
(PPM/no PPM) or ternary (severe PPM/moderate
PPM/no PPM) format. Other variables entered into
the multivariable models for adjustment were the
univariable predictors of mortality and the variables
that showed a statistically signiﬁcant difference
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1327analyses were performedwith the use of SAS software,
version 9.2 (SAS Institute Inc., Cary, North Carolina).
The Cardiovascular Research Foundation (New
York, New York) maintains the study’s database,
and independent analyses can be requested by in-
vestigators with statistical assistance provided. All of
the analyses were performed with data from the as-
implanted population. Data are based on an extract
date of February 13, 2012.TABLE 1 Baseline Clinical and Doppler Echocardiographic Characteris
According to Presence or Absence of PPM
SAVR-RCT (n ¼ 270)
No PPM
(n ¼ 108)
(40%)
PPM
(n ¼ 162)
(60%)
Demographic and clinical data
Age, yrs 84  7 85  6
Female 44.4 (48) 40.7 (66)
BSA, m2 1.79  0.23 1.85  0.22
BMI, kg/m2 26.6  5.6 27.0  5.7
Obesity, BMI $30 kg/m2 23.0 (25) 25.9 (42)
STS score 11 (10–13) 11 (10–13)
Logistic euroSCORE 26 (16–37) 27 (19–42)
Diabetes 40.7 (44) 42.0 (68)
Hyperlipidemia 80.6 (87) 87.0 (141)
Smoking 48.1 (52) 48.8 (79)
Hypertension 96.3 (104) 93.8 (152)
NYHA functional class IV 55.6 (60) 48.1 (78)
Angina 21.3 (23) 19.1 (31)
Coronary artery disease 74.1 (80) 79.0 (128)
Prior MI 25.9 (28) 30.6 (49)
Prior PCI 29.6 (32) 33.5 (54)
Prior CABG 39.8 (43) 50.0 (81)
Stroke or TIA (last 6–12 months) 31.4 (32) 25.7 (38)
Carotid disease 28.7 (29) 23.9 (34)
Peripheral vascular disease 49.5 (53) 39.9 (63)
Porcelain aorta 0.9 (1) 0.0 (0)
Pulmonary hypertension 48.1 (52) 50.6 (82)
Major arrhythmia 50.9 (55) 53.4 (86)
Permanent pacemaker 22.2 (24) 24.1 (39)
Renal disease (creatinine $2) 13.0 (14) 25.3 (41)
Liver disease 4.6 (5) 1.2 (2)
COPD 45.4 (49) 43.8 (71)
Oxygen dependent 5.6 (13) 8.0 (19)
Baseline Doppler-echocardiographic data
Aortic annulus diameter, mm 20.3  2.3 19.8  2.2
LV ejection fraction, % 56  13 53  13
AV mean gradient, mm Hg 45  14 42  15
Moderate/severe AR 10.8 (11) 15.1 (24)
Moderate/severe MR 13.7 (14) 22.8 (36)
Values are mean  SD, % (n), or median (interquartile range). Continuous variables are re
reported as median and (interquartile range) and compared with the Wilcoxon rank-sum
AR ¼ aortic regurgitation; AV ¼ aortic valve; BMI ¼ body mass index; BSA ¼ bod
euroSCORE ¼ European System for Cardiac Operative Risk Evaluation; LV ¼ left ventricu
York Heart Association; PCI ¼ percutaneous coronary intervention; PPM ¼ prosthesis-pat
Surgeons; TAVR ¼ transcatheter aortic valve replacement; TIA ¼ transient ischemic attaRESULTS
COMPARISON OF THE INCIDENCE OF PPM IN
TAVR-RCT VERSUS SAVR-RCT. The incidence of PPM
assessed at ﬁrst postoperative echocardiogram was
signiﬁcantly (p < 0.001) lower in the TAVR-RCT arm
(overall PPM: 46.4% [n ¼ 141]; moderate: 26.6%
[n ¼ 81]; severe: 19.7% [n ¼ 60]) than in the SAVR-RCT
arm (overall: 60.0% [n ¼ 162]; moderate: 31.9%tics of Patients in the TAVR and SAVR Arms of the PARTNER Trial Cohort A
TAVR-RCT (n ¼ 304) TAVR-NRCA (n ¼ 1,637)
p Value
No PPM
(n ¼ 163)
(53.6%)
PPM
(n ¼ 141)
(46.4%) p Value
No PPM
(n ¼ 920)
(56.2%)
PPM
(n ¼ 717)
(43.8%) p Value
0.55 85  6 83  8 0.02 86  6 84  7 <0.0001
0.55 39.9 (65) 44.0 (62) 0.47 48.2 (443) 48.3 (346) 0.97
0.04 1.77  0.23 1.90  0.26 <0.001 1.75  0.24 1.85  0.25 <0.0001
0.44 25.7  4.8 29.7  8.5 <0.001 25.5  5.5 27.8  6.4 <0.0001
0.67 16.2 (26) 38.0 (54) <0.001 14.9 (137) 30.7 (220) <0.001
0.45 11 (10–13) 11 (10–13) 0.92 11 (9–13) 11 (10–13) 0.32
0.12 26 (17–38) 26 (15–39) 0.85 23 (15–34) 23 (14–35) 0.81
0.84 40.5 (66) 46.8 (66) 0.27 32.6 (300) 42.8 (307) <0.0001
0.15 79.1 (129) 80.1 (113) 0.83 85.1 (783) 87.0 (624) 0.27
0.92 48.5 (79) 53.2 (75) 0.41 47.1 (433) 50.2 (360) 0.21
0.37 85.3 (139) 93.6 (132) 0.02 94.2 (867) 93.6 (671) 0.58
0.23 53.4 (87) 49.6 (70) 0.52 43.9 (403) 48.6 (348) 0.056
0.66 23.9 (39) 27.0 (38) 0.55 19.0 (175) 19.2 (138) 0.91
0.34 70.6 (115) 79.4 (112) 0.08 78.3 (720) 82.1 (589) 0.056
0.40 27.0 (44) 27.0 (38) 0.99 25.0 (229) 28.9 (206) 0.07
0.50 29.4 (48) 35.0 (49) 0.30 44.8 (412) 39.5 (283) 0.03
0.10 39.9 (65) 48.2 (68) 0.15 42.3 (389) 48.1 (345) 0.02
0.32 27.8 (42) 32.8 (44) 0.36 25.5 (232) 25.9 (183) 0.84
0.40 28.7 (43) 31.8 (42) 0.56 24.7 (223) 28.2 (197) 0.11
0.12 38.9 (63) 42.4 (59) 0.53 47.2 (431) 45.5 (320) 0.48
0.40 1.2 (2) 0.0 (0) 0.50 1.5 (14) 0.6 (4) 0.06
0.69 50.9 (83) 51.1 (72) 0.98 37.2 (337) 38.7 (276) 0.54
0.69 45.4 (74) 47.5 (67) 0.71 47.9 (440) 56.2 (403) 0.0008
0.72 22.7 (37) 17.7 (25) 0.28 20.4 (188) 23.9 (171) 0.09
0.01 17.3 (28) 17.7 (25) 0.92 15.8 (145) 16.2 (116) 0.81
0.12 1.8 (3) 2.8 (4) 0.71 2.4 (22) 2.0 (14) 0.55
0.80 39.9 (65) 48.9 (69) 0.11 39.8 (366) 46.2 (331) 0.01
0.44 8.6 (14) 9.2 (13) 0.85 6.3 (58) 10.2 (73) 0.004
0.12 19.8  2.4 20.4  2.4 0.18 18.9  2.8 18.8  2.6 0.61
0.12 53  15 50  13 0.09 54  12 51  13 0.0001
0.053 44  15 43  14 0.39 45  15 44  14 0.22
0.48 10.0 (16) 4.4 (6) 0.12 10.3 (93) 8.8 (61) 0.40
0.16 22.4 (36) 18.8 (25) 0.46 22.5 (196) 22.9 (157) 0.46
ported as mean  SD and compared with the Student t test, except the STS score and logistic euroSCORE, which are
test. Values in parentheses indicate the number of patients.
y surface area; CABG ¼ coronary artery bypass graft surgery; COPD ¼ chronic obstructive pulmonary disease;
lar; MI ¼ myocardial infarction; MR ¼ mitral regurgitation; NRCA ¼ nonrandomized continued access; NYHA ¼ New
ient mismatch; RCT ¼ randomized clinical trial; SAVR ¼ surgical aortic valve replacement; STS ¼ Society of Thoracic
ck.
TABLE 2
SAVR-RCT
SAVR-RCT
No PPM
PPM
p Value
TAVR-RCT
No PPM
PPM
p Value
TAVR-NRC
No PPM
PPM
p Value
Values are m
each of the
Abbreviat
Pibarot et al. J A C C V O L . 6 4 , N O . 1 3 , 2 0 1 4
Prosthesis-Patient Mismatch in TAVR Versus SAVR S E P T E M B E R 3 0 , 2 0 1 4 : 1 3 2 3 – 3 4
1328[n ¼ 86]; severe: 28.1% [n ¼ 76]) (Figure 1A). Similar
results were obtained if PPM was assessed at the
7-day echocardiogram (TAVR 47% vs. SAVR 61%;
p < 0.001) or 30-day echocardiogram (TAVR 42% vs.
SAVR 57%; p < 0.001).
In the patients with an aortic annulus diameter
<20 mm, the incidence of severe PPM was 19.0%
(n ¼ 24/126) in the TAVR-RCT cohort versus 33.7%
(n ¼ 35/104) in the SAVR-RCT cohort (p ¼ 0.002)
(Figure 1B). The incidence of PPM was not signiﬁcantly
different between the transfemoral and transapical
approaches in the TAVR-RCT cohort (Figure 1C).
Compared with patients in the SAVR-RCT group,
those in the TAVR-RCT group had a signiﬁcantly
higher post-procedural indexed aortic valve area
(p ¼ 0.0004) and lower transprosthetic gradients (p ¼
0.005) despite higher stroke volume (p < 0.0001)
(Online Table 1).
INCIDENCE OF PPM IN TAVR-NRCA. In the TAVR-
NRCA cohort, the incidence of overall, moderate,
and severe PPM was 43.8% (n ¼ 920), 30.2% (n ¼ 495),
and 13.6% (n ¼ 222), respectively (Figure 1A), and it
did not differ between the transfemoral and trans-
apical approaches (Figure 1C). Forty-six (2.8%) of the
patients in the TAVR-NRCA cohort underwent an
intraprocedural transcatheter valve-in-valve proce-
dure for valve malposition or dysfunction, and the
incidence of PPM was similar in this subset (overall:
47.8% [n ¼ 22]; moderate: 30.4% [n ¼ 14]; severe:
17.4% [n ¼ 8]) compared with the patients who did
not undergo this procedure (overall: 43.7% [n ¼ 695];
moderate: 30.2% [n ¼ 481]; severe: 13.5% [n ¼ 214])
(Figure 1D). Patients who underwent post-dilationImpact of PPM on LV Mass Regression at 1 Year in the
and TAVR-RCT Arms and the TAVR-NRCA Registry
LV Mass
Baseline
Absolute Change
Baseline to 1 Year
Percent Change
Baseline to 1 Year
275  80 g 61  51 g* 23% (32 to 12)*
280  88 g 36  68 g* 15% (28 to 3)*
0.70 0.02* 0.007*
275  84 g* 27  56 g 9% (19 to 4)
295  84 g* 44  63 g 10% (24 to 1)
0.05* 0.07 0.27
A
237  70 g* 40  61 g 17% (30 to 4)
247  73 g* 32  61 g 13% (24 to 2)
0.01* 0.24 0.09
ean  SD or median (interquartile range). The p value is for PPM versus no PPM in
3 cohorts. *These values underline the differences that are statistically signiﬁcant.
ions as in Table 1.(n ¼ 222; 14.2%) had signiﬁcantly (p < 0.001) less
PPM (overall: 30.6% [n ¼ 68]; moderate: 22.0%
[n ¼ 49]; severe: 8.6% [n ¼ 19]) compared with the
1,415 patients in the TAVR-NRCA cohort who did not
undergo post-dilation (overall: 45.8% [n ¼ 647];
moderate: 31.5% [n ¼ 445]; severe: 14.3% [n ¼ 202])
(Figure 1D).
COMPARISON OF BASELINE CHARACTERISTICS
ACCORDING TO PPM. In the SAVR-RCT arm, patients
with PPM on their ﬁrst postoperative echocardiogram
had similar age, sex distribution, body mass
index (BMI), and Society of Thoracic Surgeons (STS)
score compared with those with no PPM (Table 1).
However, patients in the SAVR-RCT group with
PPMhad signiﬁcantly larger BSA andhigher prevalence
of renal disease than those without PPM. The
incidence of moderate or greater total prosthetic AR
was 3%, 0%, and 0% in the no PPM,moderate PPM, and
severe PPM groups of the SAVR-RCT cohort, respec-
tively (p¼ 0.13).
In the TAVR-RCT arm, patients with PPM were
signiﬁcantly younger and had higher BSA and BMI
and larger baseline LV mass compared with those
with no PPM (Tables 1 and 2). In the TAVR-RCT cohort,
the incidence of mild or greater total prosthetic AR at
ﬁrst post-implant echocardiography was 63.1%,
57.0%, and 63.2% (p ¼ 0.42) in the no PPM, moderate
PPM, and severe PPM groups, respectively, and the
incidence of at least moderate total regurgitation was
11.5%, 10.1%, and 7.0%, respectively (p ¼ 0.63).
Table 1 shows the comparison of the baseline
characteristics between the PPM and no PPM groups
in the TAVR-NRCA arm. In this cohort, the incidence
of mild or greater AR was 56.0%, 47.3%, and 43.4%
(p < 0.001) and that of at least moderate AR was
10.6%, 8.3%, and 5.9% (p ¼ 0.07) in the no PPM,
moderate PPM, and severe PPM groups, respectively.
IMPACT OF PPM ON THE REGRESSION OF LV
HYPERTROPHY IN TAVR AND SAVR. In the SAVR-
RCT arm, there was signiﬁcantly less LV mass
regression at 1 year in the PPM group compared with
the no PPM group (Figure 2, Table 2). However, LV
mass regression was similar between the PPM and no
PPM groups in the TAVR-RCT arm. Among the pa-
tients with no PPM, those in the SAVR-RCT group
experienced signiﬁcantly more LV mass regression
than those in the TAVR-RCT group (p < 0.001),
whereas among those with PPM the extent of LV mass
regression was similar in both arms (p ¼ 0.46). In the
TAVR-NRCA cohort, there was a trend for a lesser
percent of LV mass regression in patients with
PPM than in those with no PPM in univariable anal-
ysis (Table 2).
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FIGURE 2 LV Mass Regression Over Time for the Groups of Patients
With PPM Versus no PPM
LV mass (mean  SEM) at baseline and different follow-up times according to
the presence or absence of PPM in the SAVR-RCT arm (A), TAVR-RCT arm (B),
and TAVR-NRCA cohort (C). *Signiﬁcant difference (p < 0.05) between the
PPM and no PPM groups. #Signiﬁcant difference (p < 0.05) from baseline
within each PPM group. LV ¼ left ventricular; other abbreviations as in
Figure 1.
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1329In multivariable analysis including age, sex, base-
line LV mass, baseline mitral regurgitation, and post-
procedural total AR, PPM independently predicted
lower absolute LV mass regression at 1 year in the
SAVR-RCT group (b coefﬁcient: 21  9; p ¼ 0.017)
but not in the TAVR-RCT group (b coefﬁcient: 7  8;
p ¼ 0.35). However, PPM was independently associ-
ated with less LV mass regression in the TAVR-NRCA
group (b coefﬁcient: 13  5; p ¼ 0.012). Similar
results were obtained when using percent of
LV mass regression in the multivariable analysis
(SAVR-RCT: p ¼ 0.016; TAVR-RCT: p ¼ 0.38, TAVR-
NRCA: p ¼ 0.017). Higher “residual” mean gradient
at ﬁrst post-implant echocardiography also was
associated with less LV mass regression in both the
TAVR-RCT (p ¼ 0.014) and TAVR-NRCA (p < 0.001)
groups. On multivariable analysis, there was an in-
dependent association between higher mean gradient
and less absolute LV mass regression in the TAVR-
NRCA group (b coefﬁcient: 0.61  0.18; p < 0.001)
but not in the TAVR-RCT group.
We found no signiﬁcant association between PPM
and change in LV ejection fraction from baseline to
1 year in the SAVR-RCT, TAVR-RCT, and TAVR-NRCA
groups. Similar results were obtained when the ana-
lyses were restricted to the subsets of patients with
LV ejection fraction <50% at baseline.
IMPACT OF PPM ON MORTALITY IN TAVR AND SAVR.
Thirty-day mortality was similar in the PPM and no
PPM groups in the SAVR-RCT (4.3% vs. 5.6%), TAVR-
RCT (1.8% vs. 2.1%), and TAVR-NRCA (1.6% vs. 2.2%)
groups (all p ¼ NS). Figure 3 shows the curves of all-
cause mortality according to PPM.
In the SAVR-RCT arm, patients with any degree of
PPM demonstrated signiﬁcantly higher 2-year mor-
tality (hazard ratio [HR]: 1.64; 95% conﬁdence inter-
val [CI]: 1.01 to 2.67; p ¼ 0.047) than patients with no
PPM (Figure 3A, Table 3). Compared with patients
with no PPM, those with severe PPM had an increased
risk of 2-year mortality (HR: 1.79; 95% CI: 1.03 to 3.12;
p ¼ 0.04), but those with moderate PPM did not
(HR: 1.51; 95% CI: 0.87 to 2.64; p ¼ 0.14) (Figure 3B,
Table 3). The other predictors of 2-year mortality in
univariable analysis are presented in Online Table 2.
In multivariable analysis including age, sex, BMI, STS
score, major arrhythmia, pulmonary hypertension,
renal disease, and post-procedural AR (Table 3), se-
vere PPM independently predicted 2-year mortality
(HR: 1.78; 95% CI: 1.02 to 3.11; p ¼ 0.041) in the SAVR-
RCT arm. There was also a trend toward an inde-
pendent association between overall PPM and 2-year
mortality (HR: 1.52; 95% CI: 0.93 to 2.48; p ¼ 0.09).
When restricting analysis of mortality rates to the 1-
year time period, the univariable HR was 1.82, (95%CI: 0.96 to 3.45; p ¼ 0.06) for severe PPM and 1.48
(95% CI: 0.78 to 2.83; p ¼ 0.23) for moderate PPM.
In the TAVR-RCT arm, overall PPM was not
signiﬁcantly (p ¼ 0.16) associated with 2-year
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FIGURE 3 All-Cause Mortality According to Presence and Severity of PPM
Time-to-death curves for PPM stratiﬁed in 2 groups (overall [i.e., moderate þ severe] PPM vs. no PPM) or in 3 groups (severe PPM, moderate
PPM, no PPM) for death from any cause in SAVR-RCT (A and B), TAVR-RCT (C and D), TAVR-NRCA (E and F), and TAVR-NRCA excluding
patients with mild or greater total AR (G and H). In B, D, F, and H, the log-rank p values refer to the 3-group comparison. AR ¼ aortic
regurgitation; other abbreviations as in Figure 1.
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TABLE 3 Impact of PPM on 2-Year Mortality in the
SAVR-RCT and TAVR-RCT Arms
2-Year Mortality
Univariable Analysis Multivariable Analysis*
HR (95% CI) p Value HR (95% CI) p Value
SAVR-RCT (n ¼ 270)
PPM 1.64 (1.01–2.67)† 0.047† 1.52 (0.93–2.48) 0.09
Moderate PPM 1.51 (0.87–2.64) 0.14 1.44 (0.82–2.52) 0.20
Severe PPM 1.79 (1.03–3.12)† 0.04† 1.78 (1.02–3.11)† 0.041†
TAVR-RCT (n ¼ 304)
PPM 0.74 (0.48–1.13) 0.16 0.85 (0.55–1.31) 0.46
Moderate PPM 0.92 (0.57–1.49) 0.74 1.10 (0.67–1.80) 0.70
Severe PPM 0.51 (0.27–0.98)† 0.045† 0.58 (0.30–1.13) 0.11
*Adjusted for age, sex, BMI, STS score, pulmonary hypertension, major arrhythmia, renal
disease, and post-procedural AR. †These values underline the differences that are statistically
signiﬁcant.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Table 1.
TABLE 4 Impact of PPM on 1-Year Mortality in the TAVR-NRCA Cohort
1-Year Mortality
Univariable Analysis Multivariable Analysis*
HR (95% CI) p Value HR (95% CI) p Value
TAVR-NRCA – whole cohort (n ¼ 1,637)
PPM 1.05 (0.85–1.28) 0.60 1.05 (0.76–1.44) 0.77
Moderate PPM 0.97 (0.72–1.31) 0.85 0.94 (0.69–1.29) 0.98
Severe PPM 1.23 (0.85–1.79) 0.27 1.20 (0.81–1.78) 0.35
TAVR-NRCA – subset with no AR† (n ¼ 835)
PPM 1.38 (0.91–2.09) 0.12 1.50 (0.99–2.29) 0.056
Moderate PPM 1.22 (0.76–1.95) 0.41 1.36 (0.85–2.20) 0.21
Severe PPM 1.74 (1.02–1.98)‡ 0.04‡ 1.88 (1.09–3.22)‡ 0.02‡
*Adjusted for age, sex, BMI, STS score, major arrhythmia, pulmonary hypertension, renal disease,
baseline mitral regurgitation, mean transaortic gradient, LV ejection fraction, and post-procedural
AR. †Subset in the TAVR-NRCA cohort with no or trace post-procedural total AR. In this subset,
there was no adjustment for post-procedural AR in the models. ‡These values underline the
differences that are statistically signiﬁcant.
Abbreviations as in Tables 1 and 3.
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1331mortality (Figures 3C and 3D, Table 3), whereas severe
PPM was associated with signiﬁcantly lower mortality
(HR: 0.51; 95% CI: 0.27 to 0.98; p ¼ 0.041) in uni-
variable analysis. (Other univariate predictors of
mortality in TAVR-RCT are shown in Online Table 2.)
In multivariable analysis including age, sex, BMI, STS
score, major arrhythmia, pulmonary hypertension,
renal disease, and post-procedural AR (Table 3), the
association between severe PPM and 2-year mortality
was no longer signiﬁcant (p ¼ 0.11). When restricting
the analysis of mortality rates to the 1-year time
period, the univariable HR was 0.44 (95% CI: 0.19 to
1.06; p ¼ 0.07) for severe PPM and 1.08 (95% CI: 0.61
to 1.91; p ¼ 0.80) for moderate PPM.
The univariate predictors of 1-year mortality in the
TAVR-NRCA cohort are presented in Online Table 2.
PPM was not signiﬁcantly associated with 1-year
mortality in both univariable (HR: 1.05; 95% CI: 0.85
to 1.28, p ¼ 0.60) (Figures 3E and 3F) and multivariable
analyses (Table 4). However, after excluding patients
with mild or greater total prosthetic AR, severe PPM
in the TAVR-NRCA group was independently associ-
ated with increased mortality (HR: 1.88, 95% CI: 1.09
to 3.22, p ¼ 0.02), and there was a trend (p ¼ 0.056)
toward an independent association between overall
PPM and mortality (Table 4). The impact of PPM on
mortality was not statistically different in patients
with a transfemoral approach versus those with a
transapical approach (pint ¼ 0.85).
DISCUSSION
The main ﬁndings of this study are as follows: 1) PPM
is more frequent and more often severe after SAVR
than TAVR in cohort A of the PARTNER I trial; 2) PPM
is associated with less regression of LV hypertrophy
in the SAVR-RCT arm and the TAVR-NRCA cohort, but
this association is not present in the TAVR-RCT arm;
3) PPM is associated with increased 2-year mortality
in the SAVR-RCT arm but not in the TAVR-RCT arm;
and 4) PPM is not associated with increased risk of
1-year mortality in the whole TAVR-NRCA cohort;
however, severe PPM is independently associated
with higher mortality in the subset of patients with no
residual prosthetic AR (Central Illustration).
INCIDENCE OF PPM IN TAVR VERSUS SAVR. The
incidence of PPM was lower with TAVR than with
SAVR, particularly in patients with a small aortic
annulus. This difference may be related to the supe-
rior hemodynamic performance of transcatheter
versus surgical valves (5,16) (Central Illustration).
Although the transcatheter valves are stented valves,
the stent is thinner and no sewing ring occupies the
annular space, which causes less obstruction to bloodﬂow, a difference that would be more important when
implanted in a small aortic annulus (5,16).
The present study reveals that post-dilation may
help to reduce the degree of PPM, most likely by
achieving more complete valve expansion. Previous
studies reported that balloon post-dilation also suc-
cessfully reduced paravalvular regurgitation in the
majority of patients, but may be associated with
an increased risk of cerebrovascular events (17,18).
Further studies are needed to determine whether
the beneﬁts of post-dilation outweigh its risks.
IMPACT OF PPM ON OUTCOMES IN TAVR AND SAVR.
Several previous studies and meta-analyses have
reported that PPM, particularly severe PPM, nega-
tively affects outcomes after SAVR (1,2). However,
this is the ﬁrst prospective multicenter study with
CENTRAL ILLUSTRATION Hemodynamic Sequelae After TAVR or SAVR
In patients with severe AS and high surgical risk, PPM is less frequent and less often severe
after TAVR than SAVR because of a larger EOA for a given patient’s annulus size; this he-
modynamic sequela is associated with less LV mass regression and higher mortality. On the
other hand, as shown in previous studies, paravalvular regurgitation is more frequent after
TAVR than SAVR and is associated with persistent LV hypertrophy and increased mortality.
The hemodynamic beneﬁt of TAVR over SAVR seems to be more important in the subset
ofpatientswith a small aortic annulus. AS¼ aortic stenosis; EOA¼effective oriﬁce area; LV¼
left ventricular; PPM ¼ prosthesis-patient mismatch; PVR ¼ paravalvular regurgitation;
SAVR ¼ surgical aortic valve replacement; TAVR ¼ transcatheter aortic valve replacement.
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cardiographic studies to examine the incidence and
impact of PPM on outcomes in patients randomized
to receive SAVR or TAVR. In addition, this is the ﬁrst
large multicenter study to examine the impact of
PPM on LV mass regression and survival in patients
undergoing TAVR.
This study shows that PPM is associated with
persistence of LV hypertrophy and increased 2-year
mortality in high-risk patients with severe AS under-
going SAVR. The HR for severe PPM we reported is
similar to that reported in the recent meta-analysis by
Head et al. (2). One hypothesis to explain the increased
mortality associatedwith PPM is that the persistence of
residual LV afterload and hypertrophy negatively
affect post-operative normalization of coronary ﬂow
reserve (1,19). In addition, patients with PPM experi-
ence signiﬁcantly less LV hypertrophy regression, as
seen in the SAVR group of the present study.
However, as opposed to what was observed in the
SAVR-RCT arm, PPM was not associated with
decreased regression of LV hypertrophy or increased
mortality in the TAVR-RCT arm. The differential
impact of PPM on survival in the TAVR-RCT versus
the SAVR-RCT is intriguing but may be explained, at
least in part, by the following factors:
1. In the TAVR-RCT arm, patients with PPM were
younger, had larger BMI, and had a higher preva-
lence of obesity compared with those with no PPM,
whereas these differences between the PPM and no
PPM groups were not present in the SAVR-RCT
arm. To this effect, Kodali et al. (4) reported that
greater BMI is a powerful independent predictor of
better 2-year survival (i.e., obesity paradox) in the
TAVR-RCT arm of the PARTNER Trial cohort A.
Furthermore, the indexation of the prosthetic
valve EOA to the patient’s BSA may overestimate
PPM severity in obese patients (20). This over-
estimation may have been more important in the
severe PPM group of the TAVR-RCT because there
was a high prevalence of obesity in this group.
These 2 phenomena may have contributed to the
absence of negative impact of PPM on LV mass
regression and survival in TAVR-RCT.
2. Several studies have reported that moderate–
severe AR is associated with increased mortality
after TAVR (4,21). In the TAVR cohorts of the pre-
sent study, patients with PPM had less post-
procedural AR compared with those without PPM,
whereas paravalvular regurgitation was rare in
SAVR, regardless of PPM status. Furthermore, pa-
tients in the no PPM SAVR group appeared to have
better LV mass regression and survival than
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may be explained by the fact that the former subset
had an optimal valve hemodynamic performance
(i.e., no residual AS and no paravalvular regurgi-
tation), whereas the latter subset had no residual
stenosis but often had paravalvular regurgitation
that may impair LV mass regression and adversely
affect survival (Central Illustration). Thus, para-
valvular regurgitation may have confounded or
masked the effect of PPM on LV mass regression
and survival in TAVR. This hypothesis is supported
by the fact that when excluding patients with
post-procedural AR, severe PPM became an inde-
pendent predictor of 1-year mortality in the TAVR-
NRCA cohort with an HR similar to that obtained in
the SAVR-RCT arm.
3. The counterintuitive association between severe
PPMand improved survival observed on univariable
analysis in the TAVR-RCT arm was not conﬁrmed
in the TAVR-NRCA arm, which suggests that factors
related to initial experience and learning curve
might have contributed to this association. To this
effect, the analysis of the patients in the TAVR-
NRCA group with no post-procedural AR is impor-
tant because, in this subset, the learning curve
effect was likely less powerful than in the TAVR-
RCT group and, as in the SAVR-RCT group, there
was no confounding effect of paravalvular regurgi-
tation. In this subset, the results with respect to
the impact of PPM on mortality were highly consis-
tent with those observed in the SAVR-RCT group.
STUDY LIMITATIONS AND STRENGTHS. In this study,
we used the data from a large, randomized study
with core laboratory echocardiographic data and
adjudicated outcome data. However, this analysis
was retrospective and subject to the limitations of an
observational study. In addition, 2-year outcomes
were unavailable in the NRCA cohort because events
were not adjudicated in this registry beyond 1 year.
We chose a deﬁnition of PPM on the basis of
commonly used indexed EOA criteria included in the
guidelines; other cut-points might produce different
results. Errors can occur in estimating prosthetic
valve EOA by Doppler echocardiography, particularly
in patients with transcatheter aortic valves in whom
the measurement of stroke volume in the LVOT is
challenging. However, the stroke volume measured
by Doppler in the LVOT was consistent with that
measured by the 2-dimensional echocardiographic
method (Online Table 1).
Patients who died in the periprocedural period
and/or who did not have a post-procedural echo-
cardiographic examination were excluded, possibly
introducing a survival bias. Several previous studieshave used the projected indexed EOA (i.e., the
indexed EOA calculated by dividing the normal
reference value of EOA of the prosthesis by the pa-
tient’s BSA) to identify PPM, and these studies have
demonstrated that PPM signiﬁcantly affects operative
mortality after SAVR (1,2).
In the TAVR-NRCA cohort, we performed a sub-
analysis after excluding patients with AR. Such an
analysis could not be performed in the TAVR-RCT arm
because of the limited number of patients.
In the present study, small aortic annulus was
deﬁned as an annulus diameter <20 mm as measured
by transthoracic echocardiography. This cut-point
likely corresponds to a larger diameter value when
measured by computed tomography before TAVR or
by the surgeon during SAVR. However, comparing the
incidence of PPM between TAVR and SAVR in the
small annulus subsets remains valid given that we
used the same method and criteria to deﬁne small
annulus in both arms.
It is important to emphasize that the protocol
of the PARTNER I Trial cohort A strongly discouraged
the use of valves other than the Edwards bio-
prostheses and excluded patients with a root enlarge-
ment planned in advance; therefore, the incidence
of PPM in the SAVR arm of this randomized study
may be higher than if other prosthetic valves with
higher EOA had been used. We cannot extrapolate our
results to patients who undergo alternative surgical
procedures to prevent PPM (i.e., aortic annulus en-
largement, implantation of a stentless bioprosthesis,
insertion of a homograft), although these procedures
are associated with their own perioperative risks.
CONCLUSIONS
In high-risk patients with severe AS, the incidence of
PPM is reduced after TAVR compared with SAVR.
Patients with PPM after SAVR have worse survival
and less LV mass regression than those without PPM.
Severe PPM also signiﬁcantly affected survival after
TAVR in the subset of patients with no post-
procedural AR. TAVR may be preferable to SAVR in
patients with a small aortic annulus susceptible to
PPM to enhance LV mass regression and reduce
postoperative mortality.
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PERSPECTIVES
COMPETENCY IN PATIENT CARE AND
PROCEDURAL SKILLS: TAVR may be preferred over
SAVR in high-risk patients with severe AS and small aortic
annulus diameter susceptible to PPM to enhance
regression of LV hypertrophy and reduce post-procedural
mortality.
TRANSLATIONAL OUTLOOK: Longer follow-up of
patients in clinical trials and studies of a wider variety of
prostheses are needed to fully characterize differences in
hemodynamic responses to TAVR versus SAVR.
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